Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review

por Xiao, Tian, Ali, Sanji, Mata, Danilo Giffoni M. M., Lohmann, Ana Elisa, Blanchette, Phillip S.
Publicado 2023

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline

por Blanchette, Phillip, Sivajohanathan, Duvaraga, Bartlett, John, Eisen, Andrea, Feilotter, Harriet, Pezo, Rossanna, Turashvili, Gulisa, Williams, Phillip
Publicado 2022

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis

por Stewart, Paul, Blanchette, Phillip, Shah, Prakesh S., Ye, Xiang Y., Boldt, R. Gabriel, Fernandes, Ricardo, Vandenberg, Ted, Raphael, Jacques
Publicado 2020

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data

por Raphael, Jacques, Richard, Lucie, Lam, Melody, Blanchette, Phillip S, Leighl, Natasha B, Rodrigues, George, Trudeau, Maureen E, Krzyzanowska, Monika K
Publicado 2022

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review

por Giffoni de Mello Morais Mata, Danilo, Chehade, Rania, Hannouf, Malek B., Raphael, Jacques, Blanchette, Phillip, Al-Humiqani, Abdullah, Ray, Monali
Publicado 2023

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer

por Fernandes, Ricardo, Ng, Terry L., Alzahrani, Mashari Jemaan, Raphael, Jacques, Blanchette, Phillip, Black, Morgan, Stober, Carol, Pond, Gregory R., Cella, David, Vandermeer, Lisa, Ibrahim, Mohammed, Clemons, Mark
Publicado 2023

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

por Tu, Megan M., Clemons, Mark, Stober, Carol, Jeong, Ahwon, Vandermeer, Lisa, Mates, Mihaela, Blanchette, Phillip, Joy, Anil Abraham, Aseyev, Olexiy, Pond, Gregory, Fergusson, Dean, Ng, Terry L., Thavorn, Kednapa
Publicado 2021

The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

por Blanchette, Phillip S., Lam, Melody, Le, Britney, Richard, Lucie, Shariff, Salimah Z., Ouédraogo, Alexandra M., Pritchard, Kathleen I., Raphael, Jacques, Vandenberg, Ted, Fernandes, Ricardo, Desautels, Danielle N., Chan, Kelvin K.W., Earle, Craig C.
Publicado 2021

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

por Clemons, Mark, Liu, Michelle, Stober, Carol, Pond, Gregory, Jemaan Alzahrani, Mashari, Ong, Michael, Ernst, Scott, Booth, Christopher, Mates, Mihaela, Abraham Joy, Anil, Aseyev, Olexiy, Blanchette, Phillip, Vandermeer, Lisa, Tu, Megan, Thavorn, Kednapa, Fergusson, Dean
Publicado 2021

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

por Clemons, Mark, Ong, Michael, Stober, Carol, Ernst, Scott, Booth, Christopher, Canil, Christina, Mates, Mihaela, Robinson, Andrew, Blanchette, Phillip, Joy, Anil Abraham, Hilton, John, Aseyev, Olexiy, Pond, Gregory, Jeong, Ahwon, Hutton, Brian, Mazzarello, Sasha, Vandermeer, Lisa, Kushnir, Igal, Fergusson, Dean
Publicado 2021